10:57 AM EDT, 09/05/2025 (MT Newswires) -- MannKind's ( MNKD ) game plan of enhancing its revenue base, while also advancing a potential pipeline, increases its value creation, Oppenheimer said in a Friday note.

Tyvaso inhalation solution has the potential to be a "backbone" therapy in idiopathic pulmonary fibrosis, or IPF, and it is expected to generate roughly $5.4 billion in sales in 2033, analysts Andreas Argyrides and Eka Gigauri wrote.

Additionally, the analysts said that with the addition of Furoscix, which is used to treat subcutaneous furosemide for edema in chronic heart failure and chronic kidney disease, the company will enhance its revenue stream by adding $346 million by 2030.

MannKind ( MNKD ) also expanded its partnership with United Therapeutics (UTHR) to develop a second inhalation therapy under their 2018 license and collaboration deal, the analysts said.

Oppenheimer raised MannKind's ( MNKD ) price target to $15 from $12 and maintained its outperform rating on the stock.

Shares of the company were up more than 3% in recent Friday trading.

Price: 5.55, Change: +0.21, Percent Change: +3.91